Parallel Industries Inc. Stock

Equities

EAPH

US2777741057

Biotechnology & Medical Research

Delayed OTC Markets 09:52:05 2024-04-24 am EDT 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Parallel Industries Inc. 0.00% 0.00%
Sales 2019 1.56M Sales 2020 - Capitalization 807K
Net income 2019 - Net income 2020 - EV / Sales 2019 6.27 x
Net Debt 2019 8.41M Net Debt 2020 2.48M EV / Sales 2020 -
P/E ratio 2019
-4.17 x
P/E ratio 2020
-4.29 x
Employees -
Yield 2019 *
-
Yield 2020
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Parallel Industries Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021 CI
Easton Pharmaceuticals Inc. cancelled the acquisition of Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada. CI
Easton Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019 CI
Easton Pharmaceuticals Inc. Moves its Corporate Head Office CI
Easton Pharmaceuticals Inc. acquired Supreme Sweets Inc. from Barbara and Mario Parravano. CI
Easton Pharmaceuticals Inc. Signs LOI with Licensed Producer of Cannabis to Expand its Operations and Participate in its Cannabis Edibles Division CI
Easton Pharmaceuticals Inc. Commences Cannabis Edibles Division CI
Easton Pharmaceuticals Inc. Announces Updates on its $2,600,000 Framing Contract to Construct 150 Homes as Well as Other Initiatives CI
Easton Pharmaceuticals Inc. Announces Sales Results for the Quarter Ended September 30, 2018 and December 31, 2018 CI
Easton Pharmaceuticals Inc. Provides Operational Update on CAD 2,600,000 Framing Contract CI
Easton Pharmaceuticals Announces Signing and Commencement of CAD 2,600,000 Framing Contract to Construct 150 Homes CI
Gunpowder Capital Corp. cancelled the acquisition of iBliss Inc. from Easton Pharmaceuticals Inc.. CI
Easton Pharmaceuticals Inc. signed a letter of intent to acquire Boutique Hotel and Real Estate Asset in the Heart of Toronto, Ontario, Canada. CI
Easton Mulls Acquisitions Of Operating Casino and Hotel Resort in Greece CI
Easton Pharmaceuticals Acquires Interest in Development Project with in Excess of CAD 30 Million in Profit CI
More news
1 month
0.00
Extreme 0
0.00
Current year
0.00
Extreme 0
0.00
1 year
0.00
Extreme 0
0.00
3 years
0.00
Extreme 0
0.00
5 years
0.00
Extreme 0
0.02
10 years
0.00
Extreme 0
0.06
More quotes
Managers TitleAgeSince
Chief Executive Officer - 15-06-29
Chief Operating Officer - 18-06-19
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Chief Executive Officer - 15-06-29
Corporate Secretary - 13-12-30
Chief Operating Officer - 18-06-19
More insiders
Date Price Change Volume
24-04-24 0.000001 0.00% 1,000
24-04-22 0.000001 0.00% 38,700

Delayed Quote OTC Markets, April 24, 2024 at 09:52 am EDT

More quotes
Easton Pharmaceuticals, Inc. is a development-stage company engaged in various pharmaceutical sectors and others industries. The Company has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The Company owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The Company's products are in various stages of commercialization. The Company's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.
More about the company